[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 448,552
  • Shares Outstanding, K 51,617
  • Annual Sales, $ 170,440 K
  • Annual Income, $ -193,880 K
  • EBIT $ -161 M
  • EBITDA $ -146 M
  • 60-Month Beta 1.14
  • Price/Sales 2.61
  • Price/Cash Flow N/A
  • Price/Book 4.25

Options Overview Details

View History
  • Implied Volatility 215.84% (+15.49%)
  • Historical Volatility 55.66%
  • IV Percentile 78%
  • IV Rank 36.25%
  • IV High 483.38% on 09/23/25
  • IV Low 63.68% on 09/05/25
  • Expected Move (DTE 16) 1.19 (14.17%)
  • Put/Call Vol Ratio 0.30
  • Today's Volume 185
  • Volume Avg (30-Day) 227
  • Put/Call OI Ratio 0.54
  • Today's Open Interest 7,658
  • Open Int (30-Day) 8,217
  • Expected Range 7.21 to 9.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-1.36
  • Number of Estimates 6
  • High Estimate $-1.12
  • Low Estimate $-1.61
  • Prior Year $0.12
  • Growth Rate Est. (year over year) -1,233.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.58 +10.82%
on 03/30/26
9.67 -13.13%
on 04/20/26
+0.64 (+8.25%)
since 03/27/26
3-Month
7.58 +10.82%
on 03/30/26
11.56 -27.34%
on 01/30/26
-3.20 (-27.59%)
since 01/29/26
52-Week
6.89 +21.92%
on 05/08/25
16.19 -48.12%
on 01/22/26
-1.01 (-10.73%)
since 04/29/25

Most Recent Stories

More News
REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

LOS ANGELES , April 14, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio" or "the Company") (NASDAQ: RGNX ) for violations...

RGNX : 8.40 (-3.34%)
RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

NEW YORK , April 14, 2026 /PRNewswire/ --

RGNX : 8.40 (-3.34%)
RGNX Deadline Today: Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of REGENXBIO, Inc. (NASDAQ: RGNX) between February 9, 2022 and January 27, 2026,...

RGNX : 8.40 (-3.34%)
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of the Securities Class Action Lawsuit Deadline on April 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner  James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their...

RGNX : 8.40 (-3.34%)
RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm

NEW YORK , April 14, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).

RGNX : 8.40 (-3.34%)
RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES , April 13, 2026 /PRNewswire/ --  The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against REGENXBIO Inc. ("Regenxbio"...

RGNX : 8.40 (-3.34%)
RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In REGENXBIO To Contact Him Directly To Discuss Their Options

RGNX : 8.40 (-3.34%)
RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

NEW YORK , April 9, 2026 /PRNewswire/ --

RGNX : 8.40 (-3.34%)
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

NEW YORK , April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against REGENXBIO Inc. ("Regenxbio" or the "Company") (NASDAQ: RGNX). Such investors are...

RGNX : 8.40 (-3.34%)
RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm

NEW YORK , April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of REGENXBIO Inc. (NASDAQ: RGNX).

RGNX : 8.40 (-3.34%)

Business Summary

REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver...

See More

Key Turning Points

3rd Resistance Point 9.20
2nd Resistance Point 8.94
1st Resistance Point 8.67
Last Price 8.40
1st Support Level 8.14
2nd Support Level 7.88
3rd Support Level 7.61

See More

52-Week High 16.19
Fibonacci 61.8% 12.64
Fibonacci 50% 11.54
Fibonacci 38.2% 10.44
Last Price 8.40
52-Week Low 6.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.